Leading Provider of Regulated Biomedical Waste Solutions, Designed to Be Energy-Efficient & Environmentally Responsible, Receives Strategic Resources & Capital to Continue Rapid Growth
3 Boomerang Capital (“3BC” or “3 Boomerang”), a healthcare-focused, lower middle-market private equity firm, today announced its investment in Bio-Response Solutions (“Bio-Response ” or the “Company”), a leader in sterilization and tissue digestion capital equipment, providing environmentally sustainable and innovative solutions for consumer, scientific and agricultural liquid and solid waste management. 3 Boomerang's investment in Bio-Response provides strategic resources and capital to support the Company's continued expansion in its core end markets.
https://mma.prnewswire.com/media/2563797/3_Boomerang_Logo.jpg
Founded in 2006, Bio-Response designs and builds alkaline hydrolysis equipment and specialized sterilization systems for funeral homes, crematoriums, veterinary clinics, as well as bio-containment laboratories that work with dangerous pathogens. The Company has developed state-of-the-art products and systems that provide a cleaner, energy-efficient, and environmentally responsible approach to tissue digestion and sterilization.
“We are excited to partner with Bio-Response and its leadership team as they continue to revolutionize the regulated medical waste management sector,” said Peter Wen, Principal at 3 Boomerang. “Bio-Response's technology is uniquely positioned to address both consumer demand and regulatory shifts favoring sustainable cremation alternatives, making it an exciting investment for us.”
With an installed base across funeral homes, pet crematories, and scientific institutions, Bio-Response has established itself as a leader in the regulated medical waste market.
“Since our inception, Bio-Response has been committed to pioneering a more sustainable approach to managing regulated liquid and solid waste streams. Partnering with 3 Boomerang will allow us to accelerate our mission and expand our reach, ensuring that more families and institutions have access to innovative and environmentally responsible solutions. Those solutions are backed by years of proven expertise and successful implementations across various sectors,” said Joe Wilson, Founder of Bio-Response Solutions.
Luke Wilson, CEO of Bio-Response Solutions, added, “We were particularly drawn to 3 Boomerang's deep understanding of our industry and their track record of growing mission-driven companies in adjacent end markets. With their support, we look forward to expanding our capabilities, scaling our operations, and advancing our leadership position in the evolving deathcare and scientific end markets.”
About Bio-Response Solutions
Bio-Response Solutions is a global leader in sterilization and tissue digestion capital equipment, offering advanced solutions through its two primary segments: Aquamation and Scientific. The Company's Aquamation segment provides state-of-the-art alkaline hydrolysis technology, a sustainable alternative to flame cremation that uses water, alkali, heat, and pressure to break down tissue in an energy-efficient and environmentally friendly process. The Scientific segment delivers innovative capital equipment solutions for sterilizing liquid and solid biological waste, serving high-containment laboratories in government, academic, and pharmaceutical end markets. Bio-Response's systems have been deployed in some of the world's most prestigious research institutions, reinforcing its leadership in regulated medical waste management. The Company remains committed to advancing responsible and ethical deathcare and bio-waste treatment through cutting-edge technology and environmental stewardship.
For more information, visit www.bioresponsesolutions.com.
About 3 Boomerang Capital
3 Boomerang Capital is a lower middle-market healthcare private equity firm committed to fostering creative investment partnerships with healthcare entrepreneurs acrossNorth AmericaandWestern Europe. 3BC's areas of investment focus span four key healthcare sectors: Biopharma outsourcing, medical device and diagnostic manufacturing, information technology and tech-enabled services, and alternate site care. The firm specializes in backing founder-led businesses, providing the guidance and resources needed for successful growth and innovation in the healthcare market. By strategically concentrating on four core areas, 3 Boomerang Capital is well-equipped to deliver on its mission of empowering healthcare entrepreneurs and propelling healthcare businesses to new heights. The firm is currently investing out of its flagship fund, 3 Boomerang Capital I, LP, a$376 millioninvestment vehicle.
For more information, visit https://www.3boomerang.com/
Media Contact
Alixe KluttzChief of Staff3 Boomerang Capital203.517.4763a.kluttz@3boomerang.com
https://c212.net/c/img/favicon.png?sn=NY48269&sd=2025-03-25
View original content to download multimedia:https://www.prnewswire.com/news-releases/3-boomerang-capital-announces-strategic-growth-investment-in-bio-response-solutions-302410310.html
SOURCE 3 Boomerang Capital
https://rt.newswire.ca/rt.gif?NewsItemId=NY48269&Transmission_Id=202503250830PR_NEWS_USPR_____NY48269&DateId=20250325